QRxPharma
North Sydney
About QRxPharma
QRxPharma is an Australian-based, commercial-stage specialty pharmaceutical company focused on the development and commercialization of new pain management and abuse prevention products Based on a development strategy that focuses on enhancing the clinical utility of currently approved compounds as well as bringing new products to market, the company's product portfolio includes both late and early stage clinical drug candidates with the potential for reduced risk, abbreviated development paths, and improved patient outcomes. In Q4 2013, the Company plans to refile with the US Food and Drug Administration a New Drug Application for its lead product candidate, immediate release MOXDUO®, for the treatment of acute pain. QRxPharma has entered into strategic agreements with Actavis Inc., Paladin Labs Inc. and Aspen Group for the commercialisation of immediate release MOXDUO in the US, Canada, Australia (including New Zealand and Oceania) and South Africa. The Company's clinical pipeline includes an intravenous (IV) and controlled release (CR) formulation of MOXDUO. QRxPharma is also collaborating with Aesica Formulation Development Limited, for the worldwide promotion of QRxPharma's proprietary Stealth Beadlets™ abuse deterrence technology.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $34.5M
- Funding stage: IPO
- Last round: Post-IPO Equity (Dec 2013)
- Ticker: asx:QRX
- Website: qrxpharma.com
- Phone: +1 213 291 0788
Industries & Categories
Biopharma, Biotechnology, Health Care
Social Profiles
Canonical: https://fsome.com/organization/qrxpharma-1717156 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.